.

follow-on-google-news

This small-cap stock delivered multibagger returns of 2914 percent in the past year as its share price increased from ₹ 139.00 to ₹ 4,190.00 apiece. Therefore, if an investor had invested ₹ 1 lakh in its shares a year ago, the value of their holdings would have been ₹ 30.14 lakhs today! 

Remedium Life Care, a BSE-listed stock, had announced a bonus issue in the ratio of 9:5 and it had fixed Saturday, 29 July, 2023 as the record date. Eligible shareholders will receive nine equity shares of ₹ 10 each fully paid up, for every five shares that they hold in the company as of the record date. 

Remedium Lifecare trades advanced pharmaceutical ingredients and other pharma products. The company delivered massive returns of 21392 percent in the past three years and a whopping 32222 percent returns in the past five years! 

With a market capitalization of ₹ 1,478 crores, it is a small-cap company. Remedium Lifecare has a very high return on equity of 70.92 percent. Its shares were trading at a price-to-earnings ratio (P/E) of 272, which is significantly higher than the industry P/E of 40.4, indicating that the stock might be overvalued as compared to its peers. Retail investors hold a 98.89 percent stake in it, while its promoters hold a 1.11 percent stake in the company. 

In the financial year 2022-23 (FY23), the company’s net profit skyrocketed 403 percent to ₹ 5.43 crores, against ₹ 1.08 crores in the previous financial year 2021-22 (FY22). However, its revenue increased marginally to ₹ 509.84 crores in FY23, against ₹ 504.79 crores in FY22. 

Written by Simran Bafna 

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

×